Immunome Inc. Overview

Immunome, Inc., a biotechnology company headquartered in Exton, Pennsylvania, is making strides in the healthcare sector by focusing on the development and commercialization of novel therapeutic antibodies and medicines. The company’s primary mission is to address various diseases through innovative treatments, serving patients within Pennsylvania. Immunome’s stock is actively traded on the Nasdaq stock exchange.

Financial Snapshot

As of May 8, 2025, Immunome Inc.’s stock closed at $7.46. Over the past year, the stock has experienced significant fluctuations, reaching a 52-week high of $16.81 on July 28, 2024, and a 52-week low of $5.1501 on April 8, 2025. The company’s market capitalization stands at approximately $770.92 million USD. However, the price-to-earnings ratio is currently at -1.71, indicating that the company is not yet profitable.

Company Focus and Operations

Immunome, Inc. is dedicated to advancing healthcare through its specialized focus on therapeutic antibodies and medicines. The company’s efforts are concentrated on treating a range of diseases, with a commitment to serving the healthcare needs of Pennsylvania residents. For more detailed information about Immunome’s activities and developments, interested parties can visit their official website at www.immunome.com .

Conclusion

Immunome Inc. continues to play a significant role in the biotechnology sector, with its focus on innovative treatments for various diseases. Despite the current lack of profitability, the company’s strategic initiatives and market presence position it as a noteworthy entity in the healthcare industry.